The Cancer Mortality Risk Project – Cancer Mortality Risks by Anatomic Site: Part 1 – Introductory Overview; Part II – Carcinoma of the Colon: 20-Year Mortality Follow-up Derived from 1973-2013 (NCI) SEER*Stat Survival Database

Milano, Anthony F; Singer, Richard B

doi:10.17849/insm-47-02-65-94.1

Cited by 13 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though in their study only five major cancers were considered and patients were at least 18 years of age (21). Most of the patients in this study were of age group > 40 years consistent with the age group with frequent age associated cancers as reported in other similar studies (22)(23)(24)(25)(26). Our relatively equal probability of survival between HIV positive and HIV negative cohorts could be attributed to the possible diffusing effect of unknown HIV status in this study as some of them could have been sero-positive.…”

Section: Discussionsupporting

confidence: 76%

Predictors of Mortality From a Population-Based Cancer Registry Data in Jos, Nigeria: A Resource-Limited Setting

et al. 2020

View full text Add to dashboard Cite

Background: It is a well-documented fact that worldwide cancer incidence and mortality remains high in Human Immunodeficiency Virus (HIV) infected population despite potent antiretroviral therapy. With the current capture of HIV status of cancer patients in our cancer registry at Jos Nigeria, this study aims to assess the effect of HIV on cancer mortality outcomes. Methodology: We conducted a 2-year retrospective cohort study of cancer registry data from Jos, north central Nigeria. The cancers were grouped into cervical, breast, liver, hematologic, colonic, AIDS defining, prostate and others in this study. Patients were followed up to determine their patient time contribution from time at initiation of cancer treatment to death or the end of study period. Those lost to follow-up were censored at date of their last known follow-up in clinic. Results: Out of 930 cancer cases evaluated, 52 (5.6%) were HIV positive, 507 (54.5%) were HIV negative and 371 (39.9%) did not know their HIV status. After 525,223 person-days of follow-up, there were 232 deaths leading to a crude mortality rate of 4.3 per 10,000 person-days. Median survival probability for both HIV-infected and HIV uninfected patients were equal (1,013 days). Unadjusted hazard of death was associated with greater age, HR 0.99 (95% CI: 0.98,0.99, p = 0.002); hepatitis virus, HR 2.40 (95% CI: 1.69,3.43, p = 0.001); liver cancer, HR 2.25 (95% CI:1.11,4.55, p = 0.024); prostate cancer, HR 0.17 (95% CI: 0.06,0.393, p = 0.001). In an adjusted model, only prostate cancer AHR 0.23 (95% CI: 0.12, 0.42, p < 0.001) and liver cancer AHR 2.45 (95% CI: 1.78, 5.51, p < 0.001) remained significantly associated with death regardless of HIV status. Conclusion: Having liver cancer increases risk for mortality among our cancer patients. Screening, early detection and treatment are therefore key to improving dismal outcomes.

show abstract

Section: Discussionsupporting

confidence: 76%

Predictors of Mortality From a Population-Based Cancer Registry Data in Jos, Nigeria: A Resource-Limited Setting

et al. 2020

View full text Add to dashboard Cite

show abstract

“…With an estimated 51,020 deaths in 2019, colorectal cancer is still a leading cause of cancer-related death in the U.S. [1]. Despite the advancements in cytotoxic, biological, and targeted therapy over the last 2 decades, the overall survival of metastatic colorectal cancer at 5 years is 14% [2,3]. It is increasingly acknowledged that colorectal cancer is a highly heterogeneous disease with diverse molecular and clinical features that affect therapeutic outcomes [4].…”

Section: Introductionmentioning

confidence: 99%

Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer

et al. 2020

View full text Add to dashboard Cite

Background. The prognostic implication of wild type APC (APC-WT) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) is not well defined. Methods. APC prognostic value was evaluated retrospectively in two independent cohorts of patient with MSS mCRC with a confirmatory analysis from a public data set from Memorial Sloan Kettering Cancer Center (MSKCC). Results. In comparison to the APC-mutant (APC-MT) population (n=255), APC-WT patients (n = 86) tended to be younger (59% of age <40 vs 26% of age > 50), right-sided (41.7% vs. 27%), BRAF-V600E mutated (23.3% vs. 0.8%), and KRAS WT (65.1% vs. 49.8%). Alternative WNT pathway alterations, RNF43 and CTNNB1 were over-represented in the APC-WT vs APC-MT population (7% vs 0.4% and 4.7% vs 0.4%, respectively). APC-WT patients had a worse overall survival (OS) than APC-MT patients (22.6 vs 45.6 months, p<0.0001). Using a multivariate model correcting for primary tumor location, RAS and BRAF status, APC-WT was predictive of poor survival (APC-MT vs APC-WT, HR=0.62, 95%CI 0.44-0.86, P=0.0037). The prognostic implication of APC-WT on OS was confirmed further in a similar multivariate model of 934 stage IV patients from MSKCC public database (APC-MT vs APC-WT, HR=0.63, 95%CI 0.49-0.81, p<0.0001). Conclusion. APC-WT is associated with poor OS in MSS mCRC regardless of RAS and BRAF status. Compared with APC-MT mCRC tumors, APC-WT tumors were associated with other Wnt activating alterations, including RNF43 and CTNBB1. Our data suggest alternative therapy needs to be investigated in APC-WT patients. The Oncologist 2020;9999:• • Implications for Practice: MSS mCRC patients with APC-WT had a worse OS than patients with APC-MT regardless of RAS/ RAF status. APC status should be considered as a stratification factor in prospective trials and novel therapeutic strategies need to be developed for this subgroup of patients.

show abstract

“…All data were extracted from the latest SEER database with SEER*Stat software: SEER 21 (Nov 2019 release) [ 14 ]. The SEER registry provides comprehensive cancer data including incidence and survival rates which obtained from medical records, covering up approximately 30.0% of the US population [ 14 , 30 ]. Data from 1984 to 2016 and a total of 1004 patients with ONAs were extracted from the SEER database.…”

Section: Methodsmentioning

confidence: 99%

Demographic and prognostic factors of optic nerve astrocytoma: a retrospective study of surveillance, epidemiology, and end results (SEER)

2021

View full text Add to dashboard Cite

Background Optic nerve astrocytomas (ONAs) are neurological neoplasms in the central nervous system (CNS), and they have the highest incidence rate among all the tumor types in the visual pathway. In this study, we conducted a Surveillance, Epidemiology, and End Results (SEER) -based research to explore the demographic, survival, and prognostic factors of patients diagnosed with ONAs. Methods Utilizing the SEER database, we retrospectively evaluated data of patients diagnosed with ONAs of all ages from 1984 to 2016. We used the Student’s t distribution to test variables of patients and various characteristics, and Kaplan-Meier curve to illustrate overall survival (OS) with 95.0% confidence intervals (CIs). We also performed univariate and multivariate analyses to evaluate various variables’ validity on overall survival. Results A total of 1004 cases were analyzed, and revealed that age (P<0.001, hazard ratio (HR) = 8.830, 95% CI: 4.088–19.073), tumor grade (P<0.001, HR = 1.927, 95% CI: 1.516–2.450), diagnostic confirmation (P<0.001, HR = 2.444, 95% CI: 1.632–3.660), and histology type (P = 0.046, HR = 1.563, 95% CI: 1.008–2.424) of the tumor were associated with decreased survival. Conclusions From this large, comparative study of ONAs, we found that younger age may be considered as a protective indicator, while high-grade astrocytic tumors have a worse prognosis. We also found that diagnostic confirmation and tumor grade were independent prognostic factors in this patient population.

show abstract

The Cancer Mortality Risk Project – Cancer Mortality Risks by Anatomic Site: Part 1 – Introductory Overview; Part II – Carcinoma of the Colon: 20-Year Mortality Follow-up Derived from 1973-2013 (NCI) SEER*Stat Survival Database

Cited by 13 publications

References 0 publications

Predictors of Mortality From a Population-Based Cancer Registry Data in Jos, Nigeria: A Resource-Limited Setting

Predictors of Mortality From a Population-Based Cancer Registry Data in Jos, Nigeria: A Resource-Limited Setting

Wild-type APC Is Associated with Poor Survival in Metastatic Microsatellite Stable Colorectal Cancer

Demographic and prognostic factors of optic nerve astrocytoma: a retrospective study of surveillance, epidemiology, and end results (SEER)

Contact Info

Product

Resources

About